Toremifene citrate

Toremifene citrate is an oral selective estrogen receptor modulator (SERM) which helps oppose the actions of estrogen in the body. Licensed in the United States under the brand name Fareston, toremifene citrate is FDA-approved for use in advanced (metastatic) breast cancer. It is also being evaluated for prevention of prostate cancer under the brand name Acapodene.

Toremifene is used in treating metastaticThe term for a cancer that has spread beyond its point of origin. Metastatic disease is responsible for the majority of cancer deaths. breast cancers in postmenopausal women whose cancers have either not been classified as either estrogen receptor positive or negative, or in those that have been determined to be estrogen receptor positive.

Toremifene citrate (Fareston®) is similar to Tamoxifen, in that molecules bind to estrogen receptors in breast cancers. By blocking estrogen molecules from binding sites, toremifene prevents estrogen's growth stimulating effects in the tumor. Drugs that act in this way are referred to anti-estrogens because they block the effects of estrogen in certain tissues.

Related CAS #: 89778-27-8  

Synonym: Fareston; FC 1157a; FC-1157a; NK 622; NSC 613680; Toremifene citrate.

IUPAC/Chemical Name: (Z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-amine 2-hydroxypropane-1,2,3-tricarboxylate

Appearance: Solid powder

Purity: >99% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

HS Tariff Code: 2934.99.9001